March 17, 2017 / 3:52 PM / 7 months ago

BUZZ-U.S. STOCKS ON THE MOVE-Valeant, Adobe, Tiffany

* Eikon search string for individual stock moves: STXBZ

* The Day Ahead newsletter: tmsnrt.rs/2ggOmBi

* The Morning News Call newsletter: tmsnrt.rs/2fwPLTh

U.S. stock index futures were little changed on Friday as investors looked for fresh catalysts after the U.S. Federal Reserve raised interest rates for the first time this year.

Dow Jones Industrial Average futures were up 0.15 percent at 20,971, S&P 500 futures were up 0.05 percent at 2,384 and Nasdaq 100 futures were up 0.18 percent at 5,422.75.

** VALEANT PHARMACEUTICALS INTERNATIONAL INC, Thursday close $11.20, +4.20 pct premarket

ValueAct Capital raised its stake in the Canadian drugmaker, in a move that could provide a confidence boost to the drug company three days after its largest shareholder sold out of the stock.

** ADOBE SYSTEMS INC, Thursday close $122.35, +5.12 pct premarket

The company reported better-than-expected first-quarter revenue and profit as demand for Creative Cloud package of software tools, which includes Photoshop, continued to rise.

** TIFFANY & CO, Thursday close $89.98, +4.75 pct premarket

The jeweler reported better-than-expected fourth-quarter profit, helped by strong demand for its jewelry in Japan and China, as well as price hikes and lower costs.

** CRAFT BREW ALLIANCE INC, Thursday close $14.55 The beermaker reported weak quarterly results as wholesalers reduced inventories.

** TESLA INC, Thursday close $262.05, +0.44 pct premarket

The electric car maker raised $1.2 billion in its dual financing. The company could raise up to $1.4 bln if the over-allotments for both the common stock and notes offerings are exercised in full.

** ARBUTUS BIOPHARMA CORP, Thursday close $2.85, +8.77 pct premarket

The RNAi drug developer on Thursday said it has licensed its drug delivery technology to Alexion Pharmaceuticals Inc for exclusive use in one of the company’s rare disease drug programs.

** CALADRIUS BIOSCIENCES INC, Thursday close $5.10, +55.88 pct premarket

The drugmaker reported a narrower-than-expected fourth-quarter loss. (Compiled by Akankshita Mukhopadhyay in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below